Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a …
Full ANIX analysis →
Anixa Biosciences, Inc. ranks #433 of 713
scored companies in Biotechnology by moat score — the top 61%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near ANIX in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 18
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 56
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 42
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 54
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 21
· 15% of the moat score
Scale matters only when it converts into economics.
Anixa Biosciences, Inc. (ANIX) scores 35 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #433 of 713 scored companies in Biotechnology, the top 61%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (56/100) and its weakest is Pricing Power (10/100).
How does Anixa Biosciences, Inc. compare with other Biotechnology companies?
Anixa Biosciences, Inc. ranks #433 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Vaccinex, Inc. (VCNX) at 36 just above it and Pliant Therapeutics, Inc. (PLRX) at 35 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Anixa Biosciences, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Anixa Biosciences, Inc.?
The Corporate Default template measures 6 defenses, and ANIX scores: Pricing Power (10), Cost Advantage (18), Customer Stickiness (56), Capital Efficiency (42), Resilience (54), Scale & Market Position (21). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.